focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
This is concerning from the huffington post article:
In a separate development, Nottingham-based SourceBio International has taken over the contract for a pilot scheme using mobile testing labs for “surge testing” of new variants in the UK.
The Department of Health were approached for comment.
Thoughts?
https://zageno.com/p/snpsig-real-time-pcr-genotyping-kit-for-abl1-codon-t315a-sku-path-gt-abl1-t315a/8391062
https://www.attogene.com/primerdesign-genesig-kits/
https://www.antibody-antibodies.com/supplier1328-primerdesign.html
https://www.arp1.com/snpsig-real-time-pcr-genotyping-kit-for-pecam1-codon-563-50-reactions-path-gt-pecam1-563.html
https://afsbio.com/products/snpsig-real-time-pcr-genotyping-kit-for-factorv-leiden-50-reactions
https://www.mayflowerbio.com/product~8068
https://7bioscience.com/primerdesign.html?page=229
https://www.usbio.net/kits/349063//data-sheet
They are everywhere.
Porky, the only obstacle I don’t know how they’ll overcome is the need for lab use and the time involved to return multiple test results. Yes we have VERSALAB, however i can’t see the government using those for schools.
I was thinking the key link to saliva is schools. Kids don’t like swabs up their noses, kids can’t be vaccinated yet, kids transmit the virus.
The ability to saliva test kids with them going back to school in a couple of weeks is key. Especially as it was ruled that Bojo couldn’t use LFT by the MHRA.
In the snippet I saw he didn’t directly mention PCR, did anyone see that?
The other thing I’d like to know is whether PROmate is compatible with saliva testing. That would enable quick, safe and easy testing at schools.
Porky, as I said yesterday the company has transformed and done an amazing job in the 2020 FY. Investors look at the future not the present or past. GM according to his own words doesn’t know what will happen in 2021 let alone beyond, therefore how can new investors trust him to invest.
Sadly we will stay in the £7-£8 range until either a.) we receive new contracts. b.) GM provides an operational update with some sort of forward projections. c.) we have a takeover offer.
Until that happens this won’t budge.
I don’t think there is at the moment soder as I presume they’re either negotiating phase 1 extension / phase 2 / a new contract including genomic sequencing.
What I find strange is that they never produced an RNS for Microgen being listed on the recent tender.
WBAFC, sorry I disagree. The board have to RNS something that will materially effect the SP a £250mil contract would cause the SP to go up. They can’t keep that quiet. They also couldn’t buy if they knew about it and hadn’t RNS’d it, insider trading.
Fair one. Excuse my nativity on this but I’ve never been invested in a company that has been taken over or had an offer. Wouldn’t any offer have to be put to the shareholders as technically PIs (between them) own the majority of the shares?
JRDC, very true however if it’s a ludicrously low offer it’ll be laughed off the table. I’m not even going to speculate a price as we seen plenty of examples which have ranged up to 10 x revenue (which I thought strange).
Personally if an offer has been made previously I feel it would have to create an RNS as that is price sensitive information. Companies normally rally straight to the offer price.
https://twitter.com/dpoidmonopod/status/1362103373340823553?s=21
Safe to say we are all frustrated and I think the only negative point about the company as it stands (other than the SP) is the communication and PI relations. If they had learnt from previous mistakes I have no doubt we’d be sat at £15 minimum by now rather than £7.40. Learning from mistakes is simple, do - review - then apply what you’ve learnt from. GM and the company are aware of the poor PR however seem to have an inability to adept and change. Investors don’t invest in the now, they invest in the future growth potential. As it stands no one has a clue what this company is doing, the only knowledge out there is from the excellent work of investors. I struggle to believe everything is under an NDA when the likes of Roche, Omega, Abbot etc shout from the roof tops.
AIM is risky, investors like the warm and fuzzy and hate silence as it can indicate wrongdoing / bad news being kept quiet from the CEO.
Some simple quick wins that would have helped:
1.) the >£10mil contract having an RNS.
2.) Microgen being listed on the new government tender, omega filed an RNS.
3.) a forward looking statement including some recurring contracts / orders already received for Jan / Feb.
4.) a rough breakdown of where money is coming from to prove the company isn’t solely reliant on the DHSC.
5.) don’t do an interview when you have no news, schoolboy, anyone could say the market would react negatively to that.
6.) a detailed outline of how the company intends to generate revenue post COVID, that doesn’t purely state infectious diseases.
It’s all well and good everyone saying that it’s incredible what GM has done with the company. I completely agree, it is. However that doesn’t mean it stops, you have to remember there are investors that have bought in £7-£12 and could be sat on a loss. If he doesn’t continue to look after the shareholders and transform the company the SP will go nowhere. Sadly sentiment is still rock bottom and looking across the board shareholder faith is beginning to dwindle.
I am still invested however as I have always said a varied, level headed discussion is required on a board.
https://twitter.com/drericding/status/1361300279203946497?s=21
Peka, I don’t believe it’s a thing with this virus. For measles 95% of the population had to be vaccinated to achieve herd immunity.
The figures quoted for COVID-19 were 70% vaccinated for a 95% efficacy vaccine. Obviously with variants the efficacy on average is 65%, to provide the same level of herd immunity you’d need to vaccinate 100% based on this efficacy which deteriorates over time.